OneMedPlace announced today that Peter Neupert of Health Evolution Partners and Jack Young of Qualcomm Ventures will participate in programming for the 6th Annual OneMedForum, January 7-9, 2013, in San Francisco. The two experts will take part in a panel dedicated to ‘Digital and Connected Health,’ an emerging sector with significant and diverse investment opportunities.
Atossa Genetics [Nasdaq: ATOS] is a healthcare company focused on the development and marketing of novel cellular and molecular diagnostic risk assessment products for breast cancer through the detection of precursors to breast cancer.
Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson’s disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has successfully completed experiments demonstrating that MANF has an excellent diffusion profile in the striatum of rat brains.
Fallout from the the US Supreme Court landmark decision to deny two patents to Prometheus Laboratories may complicate the future profitability of the industry. If this is indeed a precedent-setting decision, biomarker patents may now fall under the realm of “law of nature”, cutting off the prospect of exclusive market penetration that once justified the significant research and development onus in the early stages.
Implandata Ophthalmic Products GmbH, a German medical device start-up developing a technology for monitoring chronic eye diseases such as glaucoma, will be featured among the private companies presenting at the 6th Annual OneMedForum, January 7-9 in San Francisco.
At OneMedPlace, our goal is to be your eyes and ears to the biotech and life sciences sector: putting into perspective what we’ve seen so far, and providing you with snapshots of and what’s upcoming.
OneMedForum New York 2012 will offer a diagnostics panel session on the afternoon of July 12th to discuss the rapid technological advances in diagnostics and personalized medicine.
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Some experts believe large pharmaceutical companies have reached a plateau in market growth. However, that doesn’t tell the whole story, as new companies with disruptive technology have made some significant advancements in 2012.
Copyright © 2024 | WordPress Theme by MH Themes